|Title:||Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells||Authors:||Wang, Li-Tzu
Yen, B Linju
|Keywords:||autoimmune diseases; clinical trials; exosomes; extracellular vesicles; graft rejection; human; human pluripotent stem cells; liver cirrhosis; mesenchymal stem/stromal cell therapy; organ transplantation; pulmonary inflammation;autoimmune diseases; clinical trials; exosomes; extracellular vesicles; graft rejection; human; human pluripotent stem cells; liver cirrhosis; mesenchymal stem/stromal cell therapy; organ transplantation; pulmonary inflammation||Issue Date:||2021||Journal Volume:||10||Journal Issue:||9||Source:||Stem cells translational medicine||Abstract:||
Mesenchymal stem cell therapy (MSCT) for immune and inflammatory diseases continues to be popular based on progressive accumulation of preclinical mechanistic evidence. This has led to further expansion in clinical indications from graft rejection, autoimmune diseases, and osteoarthritis, to inflammatory liver and pulmonary diseases including COVID-19. A clear trend is the shift from using autologous to allogeneic MSCs, which can be immediately available as off-the-shelf products. In addition, new products such as cell-free exosomes and human pluripotent stem cell (hPSC)-derived MSCs are exciting developments to further prevalent use. Increasing numbers of trials have now published results in which safety of MSCT has been largely demonstrated. While reports of therapeutic endpoints are still emerging, efficacy can be seen for specific indications-including graft-vs-host-disease, strongly Th17-mediated autoimmune diseases, and osteoarthritis-which are more robustly supported by mechanistic preclinical evidence. In this review, we update and discuss outcomes in current MSCT clinical trials for immune and inflammatory disease, as well as new innovation and emerging trends in the field.
|URI:||https://scholars.lib.ntu.edu.tw/handle/123456789/583378||ISSN:||21576564||DOI:||10.1002/sctm.21-0021||SDG/Keyword:||preservative; acute graft rejection; adaptive immunity; adipose derived stem cell; adipose tissue; allogeneic hematopoietic stem cell transplantation; amnion; antigen presenting cell; apoptosis; autoimmune disease; biocompatibility; blood; blood storage; bone marrow; CD4+ T lymphocyte; cell differentiation; cell proliferation; chondrocyte; chondrogenesis; clinical trial (topic); coronavirus disease 2019; exosome; extracellular trap; gingiva; graft rejection; hematopoietic stem cell; hematopoietic stem cell transplantation; human; immune system; immunogenicity; immunological tolerance; immunomodulation; immunosuppressive treatment; inflammation; intensive care unit; liver; liver cirrhosis; liver regeneration; liver transplantation; menstrual blood; mesenchymal stem cell; mesenchymal stem cell transplantation; mesenchymal stromal cell therapy; multidetector computed tomography; olfactory mucosa; organ transplantation; osteoarthritis; peritoneal dialysis; placenta; pluripotent stem cell; pneumonia; quality of life; regenerative medicine; Review; risk factor; skin; stem cell preservation; stem cell transplantation; stroma cell; T lymphocyte; tissue engineering; tissue regeneration; tooth pulp; umbilical cord; umbilical cord blood; classification; cytology; drug effect; graft versus host reaction; immunology; mesenchymal stem cell; pluripotent stem cell; procedures; COVID-19; Graft vs Host Disease; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Pluripotent Stem Cells; SARS-CoV-2
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.